2 results about "Erythrose" patented technology

The present disclosure describes a recombinant yeast host cell having a first engineered metabolic pathway to convert fructose-6-phosphate (F-6-P) into acetyl-coenzyme A. The first engineered metabolic pathway comprises: a genetic modification for expressing a heterologous phosphoketolase capable of converting fructose-6-phosphate into erythrose-4-phosphate, and at least one genetic modification for decreasing native 6- phosphofructo-2-kinase activity classified under Enzyme Commission No. 2.7.1.105. Optionally, the recombinant yeast host cell comprises a second engineered metabolic pathway for convert acetyl-coA into a fermentation product. The present disclosure further describes a process for making a fermentation product. The process comprises contacting the recombinant yeast host cell described herein with a carbohydrate source under a condition allowing the conversion of at least a part of the carbohydrate into a fermentation product.

The invention relates to the technical field of metabolome biologic detection, in particular to a metabolic marker for glaucoma diagnosis, a screening method, a diagnosis model and application of the metabolic marker. The metabolism markers comprise an erythrocyte metabolism marker and a plasma metabolism marker; the red blood cell metabolism marker comprises one or more of phosphate, pyrophosphoric acid, O-decenoyl-L-carnitine, hydroxy octadecadienoyl carnitine, inosine monophosphate, inosine diphosphate, malic acid, fumaric acid, D-erythritol-4-phosphoric acid, indole-3-acetaldehyde, cadaverine, hypoxanthine, ornithine, arginine and tyrosine; the plasma metabolism marker comprises one or more of sphingosine 1 phosphate, pyruvic acid, allantoate, 2-ketoglutaric acid, 5-oxoproline, malic acid, ornithine, fumarate, 5-L-glutamyl-L-glutamine, catechol-3-sulfonic acid, achloroanthocyanidin, L-aspartic acid, spermine, L-arginine or 5-hydroxyisouric acid.